United States: SDNY Applies Preemption In Favor Of Branded Drug

Recently we commenced the dreary process of taking down the Christmas decorations. The German nutcrackers slid back into their cartons. Stockings marched from the mantle into plastic storage containers. We picked the ornaments off the tree, one by one, paying special attention to the souvenirs from this year's trips (Newport mansions, the FBI tour, Comic-Con). After clearing out so many of these jolly gee-gaws, we spotted a present under the tree that had thus far gone unnoticed. This seems to happen every couple of years and never fails to make us feel simultaneously silly and grateful. Our carelessness somehow managed to extend the holiday.

The Utts v. Bristol-Myers Squibb Co., et al., 2016 WL 7429449 (S.D.N.Y. Dec. 23, 2016), is like a late-discovered Christmas present. Indeed, the court's application of preemption in favor of a branded pharmaceutical is so strong, so compelling, and so useful, that it might have deserved spot on our 2016 top ten list.

The plaintiffs claimed that Eliquis, a drug used to reduce risks of stroke and embolism from a-fib, caused severe internal bleeding injuries. The complaint set forth the usual panoply of product liability actions under California law (the parties agreed that California law would apply) plus a claim under New York's consumer protection law. The court was skeptical about that last bit, dismissed it, and afforded plaintiffs with leave to amend. The court was more than skeptical about the product liability claims, as we shall see momentarily. The court also did something very shrewd. It asked the parties to identify a motion to dismiss that might dispose of the case, and then held off initiation of discovery until resolution of that motion. Here, at last, is a court that has a proper sense of the burdens of discovery and the legal frailty of many plaintiff claims.

The motion to dismiss challenged most of the claims on preemption grounds. That is the issue of most interest to us. But the defendants also prevailed on some other grounds, which we will summarize briefly in our rush to celebrate the preemption ruling:

  • The court dismissed the manufacturing defect claim because, like most such claims, it utterly failed to allege any deviation from specs.
  • The court dismissed the strict liability design defect claim because California permits no such claim against prescription drugs.
  • The court concluded that the claims for breaches of express and implied warranties were deficient because the plaintiffs never identified precisely what those warranties were. The claims were dismissed (yay) but the plaintiffs were given leave to amend (boo).
  • The court dismissed the fraud claims to the extent the FDA was the alleged victim because Buckman preemption thwarted those claims. To the extent that the alleged fraud supposedly hoodwinked anyone else, the court dismissed for lack of particularity under Fed. R. Civ. P. 9(b), but ... sigh ... the plaintiffs were permitted to try again.

There is one other point worth mentioning before plunging into the preemption analysis. It seems to us that the Eliquis label had as strong a warning as one could want regarding the alleged injuries. It discussed the risk of internal bleeding, even "serious, potentially fatal, bleeding." It disclosed that there was no established way to reverse the anticoagulant effect and that no specific antidote was available. Naturally, the plaintiffs argued that there were other things that should have been inserted into the label, but the examples supplied seem like pure fly-specking. To our plainly biased eyes, the label was plainly adequate. But the court declined to rule on the adequacy of the label. Maybe that is not such a big deal from a larger perspective, because not all labels will be as strong as the Eliquis label, but the court's preemption analysis will be relevant for many, if not most, branded pharmaceutical cases going forward. Still, it is irksome how plaintiffs get away with so much gamesmanship when it comes to retrospective critiques of product labels. Wouldn't it be wonderful if Congress passed a law requiring that plaintiffs first petition the FDA to change a label before they could institute a product liability action challenging the adequacy of a label? What would that do to litigation dockets around the country? But here we are greedily asking for another gift after pawing one we just received.

So let's talk about the court's marvelous explication of preemption principles.

The Utts court lays out a description of the Wyeth v. Levine, Pliva v. Mensing, and Mutual Pharmaceutical v. Bartlett suite that is as clear and useful as we have seen anywhere. In particular, the Utts court makes clear that there are limits to the scope of Levine's anti-preemption reach, and that the logic of Mensing and Bartlett is not limited to generic drugs. Here are the key principles the Utts court distilled from those SCOTUS cases:

  • Levine. The FDA's premarket approval of a drug includes the exact text of the label. After approval, a manufacturer may make certain changes to the label via the changes being effected (CBE) process if the manufacturer finds newly acquired information implicating safety issues. Failure to warn claims based on newly acquired information are not preempted. But Levine "did not address whether a state law failure to warn claim addressed to the NDA process was preempted." The Utts court concludes that such claims are preempted.
  • Mensing. Generic manufacturers are limited by the sameness requirement when it comes to product labels. That is, their labels must be the same as branded labels. Generic manufacturers cannot avail themselves of the CBE process. The plaintiffs suggested that the generic manufacturers could have proposed changes to the FDA, which might then work with the brand manufacturer to change the label. But SCOTUS refused to allow plaintiffs to play the what-if game. Instead, SCOTUS held that "when a party cannot satisfy its state duties without the Federal Government's special permissions and assistance, which is dependent on the exercise of judgment by a federal agency, that party cannot independently satisfy those state duties for preemption purposes." (Mensing, 564 U.S. 604, 623-24 (2011)). That independence principle is not limited to generic manufacturers. We have been saying as much in this space for quite some time. See here, for example.
  • Bartlett. The sameness requirement in Mensing applies to product design just as much as to product labels. Generic manufacturers lack the power to change product design without FDA action. (For that matter, branded manufactures cannot make major design changes without FDA action.) What, then, would the plaintiff in Bartlett, have the manufacture do? The plaintiff's argument was that the defendant could have complied with both federal and state law simply by ceasing to sell the product. But in Bartlett, SCOTUS explicitly rejected the stop-selling rationale.

Reading these three cases together, the Utts court arrives at important conclusions. The lack of authority of generic manufacturers to change labels or designs – which was discussed in Mensing and Bartlett – "exists for brand name manufacturers at the time the NDA concludes." Thus, if a claim "addresses newly acquired information and addresses a design or labeling change that a manufacturer may unilaterally make without FDA approval, then there may be no preemption of the state law claim." But post-approval design changes that would require FDA approval are preempted (citing Yates v. Ortho-McNeil-Janssen Pharm. Inc., 808 F.3d 281, 298 (6th Cir. 2015) – a case that was, by the way, our favorite case in 2015, and was praised by us in several other posts, including here), and so are label changes if they are based on information known to FDA prior to approval of the label (citing In re Celexa & Lexapro Mktg. & Sales Practices Litig., 779 F.3d 34, 43 (1st Cir. 2015) – which was only our third favorite case in 2015).

How did all of this apply to the Utts case? Very nicely for the defense. The complaint focused on the results of a study that had concluded prior to NDA . This was not "newly acquired information" of a "different type or greater severity or frequency than previously included in submissions to FDA." To be sure, the plaintiffs tried to point to newly acquired information, in the form of adverse event reports of severe hemorrhaging. Of course, there will always be adverse event reports post-approval. But the issue is whether such reports represent a different type or greater severity or frequency of injury as compared to what was revealed to FDA at the time of approval. The Utts court held that these adverse event reports constituted a "threadbare" allegation that failed to constitute newly-acquired preemption. Accordingly, the failure to warn claim was preempted. The plaintiffs have leave to amend, and we will be watching. This issue, in a manner similar to the overall adequacy of warning issue, seems ripe for plaintiff gamesmanship, and we fervently hope that courts will shut down the game.

The court also held that the negligent design claim was preempted. The plaintiffs argued that the defendants had a preapproval duty to submit a differently designed drug for FDA approval. But then the court would have to engage in "counterfactual' speculation as to whether the FDA would have approved such a design and whether such a new design would have avoided the alleged injury. The Utts court declined to speculate. Moreover, the plaintiffs' argument comes very close to replicating the stop-selling argument foreclosed in the Bartlett case. Thus, the Utts court concluded that the design defect was preempted. Even better, the Utts court dismissed the design defect claims with prejudice, with no leave to amend. Nothing the plaintiffs might say could alter the fact that the defendants simply had no ability to alter the composition of the drug without FDA approval.

Perhaps we are still under the influence of the season's shiny lights and wassailing, but Utts makes us giddy. Its reasoning is unassailable. Its effect is to undermine many failure to warn claims. It might even doom most design defect claims (for devices as well as drugs), at least if courts apply the reasoning rigorously and force plaintiffs to stop playing vague shell games and actually specify their suggested design changes. Unwrapping Utts brought us as much joy as any sled, toy, or bacon-of-the-month membership.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.